ClinicalTrials.gg
RecruitingNCT04404062Updated Jun 17, 2026

Serological and PCR Testing for COVID-19

An observational study in COVID-19, sponsored by Richmond Research Institute. Recruiting at 1 site in United Kingdom. Open to participants aged 5 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-17.

Sponsored by Richmond Research Institute · Observational

How we know

From the registry’s dates

  • Started Mar 2020; still recruiting 6 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,500
Ages
5 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 340 studies in COVID-19 with a site in United Kingdom — 17 open to participants now, 32 under way, 7 of them phase 3. COVID-19 · United Kingdom.

Planned enrollment
33rd of 167
2,500 · median 296
Started
2020
with 191 others
Observational
167 of 340
9 open now
Primary completion
2028-12
later than 30 of 31 live
Registered
72nd of 340
by date

Among the 340 studies in COVID-19 with a site in United Kingdom, this one is the 33rd largest by planned enrollment of the 167 observational ones that give a count, is one of 192 that started in 2020, is one of 167 observational ones, reaches primary completion later than 30 of the 31 other live ones, and was the 72nd registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

17 of the 340 studies in COVID-19 with a site in United Kingdom are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 5 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 340 studies in COVID-19 with a site in United Kingdom, or all of them as a file.
02

Study summary

Richmond Research Institute (RRI) is applying existing and new COVID-19 PCR and antibody tests to help develop methodologies which provide fast and accurate results. Infection with coronavirus (SARS-CoV-2) is currently a worldwide pandemic and reliable testing for COVID-19 is crucial to understand who is infected and therefore a risk to others by spreading the infection. RRI are currently carrying out the following tests:

A. Using a membrane-based immunoassay to detect IgG and IgM antibodies to SARS-CoV-2 in whole blood, serum or plasma specimens helps to assess whether an individual has previously had the virus and is potentially immune

B. Polymerase Chain Reaction (PCR) testing using an established method to check for active SARS-CoV-2 infections.

C. Quantification of anti-SARS-CoV-2 IgG and IgM antibodies in whole blood samples.

The above tests are being used by RRI to follow infections (PCR) and immunity (IgG) in their workforce, as well as their families (including children) and visitors to their site.

Collecting this data allows the gathering of epidemiological data on SARS-CoV-2 including incidence, prevalence, information on asymptomatic carriers and efficacy of vaccination. Furthermore, identifying individuals that are infected with SARS-CoV-2 has great potential to improve health outcomes by allowing infected individuals to seek the correct medical treatment as well as self-isolate and reduce transmission.

Read the detailed description

This is a screening study to measure symptomatic and asymptomatic carriage of SARS-CoV-2 in trial participants to help facilitate early detection of a second wave of SARS-CoV-2 infections. Specifically, this study aims to determine ; to assess the duration of immunity by assessing the number and speed at which trial participants were infected and cleared the virus with or without symptoms; and to determine the length of symptom onset in those with an active infection; levels of IgG antibodies by demographics (sex, age, ethnicity, and intensity of symptoms). Longitudinal assessment of antibody levels will additionally allow for assessment of the efficacy of any vaccines adminstered. This study also seeks to explore how many people are asymptomatic carriers. In addition, this study aims to help facilitate the development a quantitative laboratory reference test for antibodies (IgG).

By using multiple different tests, it can be determined if a person is currently infected with SARS-CoV-2 or whether they previously have been infected. This allows for the scanning of people with asymptomatic carriage of the virus, which is important to help reduce the spread of SARS-CoV-2 through contact with people unaware of infection.

Polymerase Chain Reaction (PCR) testing is routinely used to check for active SARS-CoV-2 infections. It measures whether viral RNA is present in an individual's system. All in-house PCR tests are verified by an independent laboratory to check for false positives.

Using a membrane-based immunoassay to detect IgG and IgM antibodies to SARS-CoV-2 in whole blood, serum or plasma specimens helps to assess whether an individual has previously had the virus and is potentially immune. IgG and IgM detection components are separate allowing for differential detection of each antibody.

To this date, 20904 PCR tests and 6848 antibody tests have been carried out in 2328 individuals, providing some interim data. Of the 20904 PCR tests, 17635 (84%) were negative and 132 (1%) were negative. Of the 6848 antibody tests, 706 (10%) were positive for IgG only, 64 (1%) were positive for IgM only, and 351 (5%) were positive for both IgG and IgM. 5710 (83%) tests were negative.

Of those individuals with a positive PCR test, 53% reported fever during the previous two months and 75% reported a loss of taste during the previous two months.

Interim results are shown in the medRxiv papers below:

https://www.medrxiv.org/content/10.1101/2020.12.08.20245894v2

https://www.medrxiv.org/content/10.1101/2021.04.09.21255200v1

03

Conditions studied

  • COVID-19

Browse trials for

04

Who can participate

Ages eligible
5 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Participants are individuals who are screened upon entry to the Richmond Pharmacology unit. These individuals may be employees of Richmond Pharmacology, volunteers for other concurrent studies, or members of the public.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged 5 to 70 years.
  • An understanding, ability, and willingness to fully comply with the project procedures and restrictions.

Exclusion criteria

Exclusion Criteria:

  • Not applicable.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,500 participants (estimated)
Patient registry
No

Groups and cohorts

  • Trial Participants

    Male and female participants aged 5-70 years

    Diagnostic Test: Membrane-based immunoassay kit · Diagnostic Test: Quantitative antibody Tests · Diagnostic Test: PCR Test

Interventions

  • Diagnostic testMembrane-based immunoassay kit

    The kit is a qualitative membrane-based immunoassay to detect IgG and IgM antibodies to SARS-CoV-2 in whole blood, serum or plasma specimens. IgG and IgM detection components are separate allowing for differential detection of each antibody.

    Also known as: Covid-19 Rapid Test Kit

  • Diagnostic testQuantitative antibody Tests

    Antibody titres will be measured from whole blood samples taken from volunteers.

    Also known as: Antibody titre

  • Diagnostic testPCR Test

    PCR tests will be conducted on throat swabs taken from volunteers.

06

What researchers measure

Primary outcomes

  1. Identification of carriers of SARS-CoV-2

    To identify trial participants who are symptomatic or asymptomatic carriers of SARS-CoV-2 by comparing the results of a blood finger stick test and reference laboratory tests to PCR testing for acute infection

    Time frame: Through study completion, estimated 12 weeks

Secondary outcomes

  1. Determination of the duration of immunity to SARS-CoV-2

    To determine the duration of immunity of trial participants previously infected with SARS-CoV-2, measure differences in IgG antibodies by demographics including sex, ethnicity and age and investigate correlation between IgG antibody levels and intensity of symptoms

    Time frame: Through study completion, estimated 12 weeks

  2. Development of a quantitative laboratory reference test for the measurement of SARS-CoV-2

    Determination of the understanding of the quantity of IgG antibodies developed as a response to SARS-CoV-2 infection, and how these antibody levels decrease over time. Antibody titres will be measured in infected individuals, over multiple days and correlated with disease parameters. This will facilitate the development of a quantitative laboratory reference test for IgG antibodies

    Time frame: Through study completion, estimated 12 weeks

  3. Exploration of SARS-CoV-2 epidemiology

    To help develop a quantitative laboratory reference test for antibodies (IgG) to gain an understanding of quantity of antibodies that people develop and how these decrease over time.

    Time frame: Through study completion, estimated 12 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2020 (actual). Primary completion is estimated for Dec 2028, 104 months after the start.

Of 134 industry-sponsored observational studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 19. This study's planned 104 months is above that.

Counting every sponsor, half of 1,774 studies reached it within 13 months; a quarter within 5 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2020
First posted
May 27, 2020
StartActual
Mar 16, 2020
Primary completionEst.
Dec 1, 2028
CompletionEst.
Dec 2028
Last update
Jun 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04404062
Lead sponsor
Richmond Research Institute
Collaborators
Richmond Pharmacology Limited
Responsible party
Sponsor
First posted
May 27, 2020
Start date
Mar 16, 2020
Primary completion
Dec 1, 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Jun 17, 2026

Study contacts

Jorg Taubel, MD
Contact
j.taubel@richmondpharmacology.com
+44(0)2070425800
Ulrike Lorch, MD
Contact
u.lorch@richmondpharmacology.com
+44(0)2038482005
Jorg Taubel, MD
principal investigator · Richmond Pharmacology Limited

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion